Paradigm Biopharmaceuticals logo

PAR - Paradigm Biopharmaceuticals Share Price

A$2.46 0.2  7.9%

Last Trade - 5:10am

Sector
Healthcare
Size
Small Cap
Market Cap £291.6m
Enterprise Value £244.1m
Revenue £2.30m
Position in Universe 396th / 1839
Bullish
Bearish
Unlock PAR Revenue
Momentum
Relative Strength (%)
1m -4.18%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -41.2%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 30th Jun 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
0.007 1.39 1.85 2.74 3.25 4.70 3.40 8.60 +264.2%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the six months ended 31 December 2020, ParadigmBiopharmaceuticals Ltd revenues decreased 69% to A$254K.Net loss increased from A$5.1M to A$20.7M. Revenues reflecta decrease in demand for the Company's products andservices due to unfavorable market conditions. Higher netloss reflects Research and development expenses increasefrom A$4.3M to A$17.2M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

PAR Revenue Unlock PAR Revenue

Net Income

PAR Net Income Unlock PAR Revenue

Normalised EPS

PAR Normalised EPS Unlock PAR Revenue

PE Ratio Range

PAR PE Ratio Range Unlock PAR Revenue

Dividend Yield Range

PAR Dividend Yield Range Unlock PAR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
PAR EPS Forecasts Unlock PAR Revenue
Profile Summary

Paradigm Biopharmaceuticals Limited is a biopharmaceutical company focused on repurposing the drug pentosan polysulfate sodium (PPS) for the treatment of inflammation. The Company is engaged in researching and developing therapeutic products for human use. The Company is a drug repurposing company, which seeks to find new uses for old drugs. The Company has commenced the open labelled Phase II clinical trial, investigating the role of the drug PPS in treating traumatic Bone Marrow Lesions. The Company's Rhinosul has properties consisting of both histamine stabilizing and anti-inflammatory properties. The Company focuses on repurposing PPS under ZILOSUL name, as a treatment for bone marrow edema (BME) lesions following traumatic injury.

Directors
Last Annual June 30th, 2020
Last Interim December 31st, 2020
Incorporated May 2, 2014
Public Since August 20, 2015
No. of Shareholders: 14,881
No. of Employees: n/a
Sector Healthcare
Industry Biotechnology & Medical Research
Index S&P/ASX All Ordinaries , S&P/ASX 300 , ASX Small Ordinaries ,
Exchange Australian Stock Exchange - SEATS
Shares in Issue 229,169,548
Free Float (0.0%)
Eligible for
ISAs
SIPPs
PAR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for PAR
Upcoming Events for PAR
Frequently Asked Questions for Paradigm Biopharmaceuticals
What is the Paradigm Biopharmaceuticals share price?

As of 5:10am, shares in Paradigm Biopharmaceuticals are trading at A$2.46, giving the company a market capitalisation of £291.6m. This share price information is delayed by 15 minutes.

How has the Paradigm Biopharmaceuticals share price performed this year?

Shares in Paradigm Biopharmaceuticals are currently trading at A$2.46 and the price has moved by -22.18% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Paradigm Biopharmaceuticals price has moved by -28.28% over the past year.

What are the analyst and broker recommendations for Paradigm Biopharmaceuticals?

Of the analysts with advisory recommendations for Paradigm Biopharmaceuticals, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Paradigm Biopharmaceuticals is Hold. You can view the full broker recommendation list by unlocking its StockReport.

When will Paradigm Biopharmaceuticals next release its financial results?

Paradigm Biopharmaceuticals is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Paradigm Biopharmaceuticals dividend yield?

Paradigm Biopharmaceuticals does not currently pay a dividend.

Does Paradigm Biopharmaceuticals pay a dividend?

Paradigm Biopharmaceuticals does not currently pay a dividend.

When does Paradigm Biopharmaceuticals next pay dividends?

Paradigm Biopharmaceuticals does not currently pay a dividend.

How do I buy Paradigm Biopharmaceuticals shares?

To buy shares in Paradigm Biopharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Paradigm Biopharmaceuticals?

Shares in Paradigm Biopharmaceuticals are currently trading at A$2.46, giving the company a market capitalisation of £291.6m.

Where are Paradigm Biopharmaceuticals shares listed? Where are Paradigm Biopharmaceuticals shares listed?

Here are the trading details for Paradigm Biopharmaceuticals:

Country of listing: Australia
Exchange: ASX
Ticker Symbol: PAR
What kind of share is Paradigm Biopharmaceuticals?

Based on an overall assessment of its quality, value and momentum, Paradigm Biopharmaceuticals is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Paradigm Biopharmaceuticals share price forecast 2021?

Shares in Paradigm Biopharmaceuticals are currently priced at A$2.46. At that level they are trading at 10.83% discount to the analyst consensus target price of 0.00.

Analysts covering Paradigm Biopharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -0.166 for the next financial year.

How can I tell whether the Paradigm Biopharmaceuticals share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Paradigm Biopharmaceuticals. Over the past six months, the relative strength of its shares against the market has been -25.48%. At the current price of A$2.46, shares in Paradigm Biopharmaceuticals are trading at -18.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Paradigm Biopharmaceuticals PE Ratio?

We were not able to find PE ratio data for Paradigm Biopharmaceuticals.

Who are the key directors of Paradigm Biopharmaceuticals?

Paradigm Biopharmaceuticals's management team is headed by:

Paul Rennie - CHM
John Gaffney - NID
Kevin Hollingsworth - SEC
Donna Skerrett - EDR
Ravi Krishnan - CSO
Amos Meltzer - NID
Helen Fisher - NED
Who are the major shareholders of Paradigm Biopharmaceuticals?

Here are the top five shareholders of Paradigm Biopharmaceuticals based on the size of their shareholding:

Rennie (Paul) Individual Investor
Percentage owned: 8.9% (20.1m shares)
RBC Global Asset Management (Asia) Limited Investment Advisor
Percentage owned: 3.9% (8.81m shares)
RBC Asia Pacific ex-Japan Equity Fund Mutual Fund
Percentage owned: 3.89% (8.79m shares)
Allianz Global Investors Asia Pacific Limited Investment Advisor/Hedge Fund
Percentage owned: 2.05% (4.62m shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 1.73% (3.91m shares)
Similar to PAR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.